The ongoing clinical debate, will now be to understand whether MTC patients should be treated with MKI or RET-specific inhibitors, to which genotypes the response will be more efficient and what the timing of therapy administration should be, i.e., if we should anticipate them and consider them as first-line options. Here, RET is linked to medullary thyroid gland carcinoma.